PMID- 37529247
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230803
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Combination of Chinese herbal medicine and conventional western medicine for 
      coronavirus disease 2019: a systematic review and meta-analysis.
PG  - 1175827
LID - 10.3389/fmed.2023.1175827 [doi]
LID - 1175827
AB  - OBJECTIVE: This study aimed to assess the efficacy and safety of Chinese herbal 
      medicine (CHM) plus conventional western medicine (CWM) in comparison with CWM 
      against COVID-19. METHODS: We searched eight electronic databases and three trial 
      registers spanning from January 1, 2020 to May 18, 2023. We included randomized 
      controlled trials (RCTs) comparing the effectiveness and safety of CHM plus CWM 
      and CWM against COVID-19 in our study. The Cochrane Risk of Bias tool 2.0 (RoB2) 
      was applied to evaluate the methodological quality of the included RCTs. The 
      Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
      system was employed to assess the certainty of evidence. Statistical analysis was 
      implemented in R version 4.1.2. RESULTS: Our study included 50 RCTs involving 
      11,624 patients. In comparison with sole CWM, CHM plus CWM against COVID-19 
      significantly enhanced clinical effective rate (RR = 1.18, 95% CI [1.13, 1.22]), 
      improved chest image (RR = 1.19, 95% CI [1.11, 1.28]), inhibited clinical 
      deterioration (RR = 0.45, 95% CI [0.33, 0.60]), lowered mortality (RR = 0.53, 95% 
      CI [0.40, 0.70]), and reduced the total score of TCM syndrome (SMD = -1.24, 95% 
      CI [-1.82, -0.66]). SARS-CoV-2 nucleic acid conversion time (MD = -2.66, 95% CI 
      [-3.88, -1.44]), duration of hospitalization (MD = -2.36, 95% CI [-3.89, -0.82]), 
      and clinical symptom (fever, cough, fatigue, and shortness of breath) recovery 
      times were shorter in CHM plus CWM groups than in CWM groups. Further, CHM plus 
      CWM treatment was more conducive for some laboratory indicators returning to 
      normal levels. No statistical difference was found in the incidence of total 
      adverse reactions between the two groups (RR = 0.97, 95% CI [0.88, 1.07]). We 
      assessed the risk of bias for 246 outcomes, and categorized 55 into "low risk", 
      151 into "some concerns", and 40 into "high risk". Overall, the certainty of the 
      evidence ranged from moderate to very low. CONCLUSIONS: Potentially, CHM listed 
      in this study, as an adjunctive therapy, combining with CWM is an effective and 
      safe therapy mode for COVID-19. However, more high-quality RCTs are needed to 
      draw more accurate conclusions. CLINICAL TRIAL REGISTRATION: 
      https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=293963.
CI  - Copyright (c) 2023 Tong, Ma, Zhou, Yang, Yang, Luo, Huang and Wang.
FAU - Tong, Lei
AU  - Tong L
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Ma, Zhenyu
AU  - Ma Z
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Zhou, Yixiao
AU  - Zhou Y
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Yang, Shuping
AU  - Yang S
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Yang, Yalin
AU  - Yang Y
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Luo, Jingran
AU  - Luo J
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Huang, Junbo
AU  - Huang J
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
FAU - Wang, Fucai
AU  - Wang F
AD  - School of Medicine, Huaqiao University, Quanzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20230717
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10387529
OTO - NOTNLM
OT  - COVID-19
OT  - Chinese herbal medicine
OT  - meta-analysis
OT  - randomized controlled trials
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/02 06:43
MHDA- 2023/08/02 06:44
PMCR- 2023/07/17
CRDT- 2023/08/02 03:53
PHST- 2023/02/28 00:00 [received]
PHST- 2023/06/29 00:00 [accepted]
PHST- 2023/08/02 06:44 [medline]
PHST- 2023/08/02 06:43 [pubmed]
PHST- 2023/08/02 03:53 [entrez]
PHST- 2023/07/17 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1175827 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Jul 17;10:1175827. doi: 10.3389/fmed.2023.1175827. 
      eCollection 2023.